Update: Xadago European roll-out continues
At its FY15 results Newron reported €0.5m (vs our €0.8m estimate) in royalties from commercial partner, Zambon after seven months of Xadago (Parkinson’s disease therapy) sales in Germany. So far in 2016 Zambon has also launched Xadago in Italy, Switzerland and Spain. The Xadago US PDUFA date is 29 March 2016, and a Xadago sublicensing deal in the US and a potential partnership for NW-3509 are on the cards. We have lowered our valuation slightly to CHF504m (vs CHF522m) primarily to reflect an increase in R&D expenses to support the mid-stage pipeline.Newron Pharmaceuticals is a clinical stage biopharmaceutical company. Co. is focused on the development of drugs for the treatment of central nervous system disorders and pain. Co.'s pipeline include, Xadago® (safinamide), for the treatment of Parkinson's disease (PD) and PD Levodopa-induced dyskinesia; Sarizotan, for the treatment of Rett syndrome (Orphan drug status); Evenamide (NW-3509), for the treatment of Schizophrenia and Clozapine-treatment-resistant schizophrenia; and Ralfinamide for patients with specific rare pain indications (neuropathic pain).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.